Evaluation of the Efficacy and Safety of Interleucin-2 Combined With PD-1 Monoclonal Antibody and CAPOX in Preoperative Neoadjuvant Therapy for Mid-low Locally Advanced Rectal Cancer - a Single-center, Single-arm, Open-label Clinical Trail

Summary

Evaluation of the efficacy and safety of interleucin-2 combined with PD-1 monoclonal antibody and CAPOX in preoperative neoadjuvant therapy for mid-lower locally advanced rectal cancer - a single-center, single-arm, open-label clinical trail.

Timeline

Start

2023-10-21

Primary completion

2024-12-31

Completion

2024-12-31

Publications

• Tang J, Wang L, Yang S, Peng W, Zhang Y, Zhang Y, Jin K, Wang X, Feng Y, Sun Y. Total neoadjuvant chemotherapy combined with PD-1 blockade and IL-2 in MSS/pMMR locally advanced rectal cancer: short-term results of a prospective, single-arm phase II study. Signal Transduct Target Ther. 2026 May 4;11(1):163. doi: 10.1038/s41392-026-02683-8.

Drugs

Indications